Deal facts
- Buyer
- Janel Corporation
- Target
- EnCor Biotechnology Inc.
- Deal value
- USD 17,000,000
- Announced
- 22 October 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash, loan-note
Sources
Janel Corporation, through its wholly owned subsidiary Antibodies Incorporated, completed the acquisition of EnCor Biotechnology Inc. on October 20, 2026. Under the Purchase Agreement, Antibodies Inc. acquired 100% of the issued and outstanding shares of common stock of EnCor, a Gainesville, Florida-based company that develops, manufactures, and distributes antibodies and reagents used in the research and treatment of neurological diseases and conditions.
Consideration consisted of $11,960,000 in closing cash plus a subordinated promissory note dated October 20, 2026 with a principal amount of $5,040,000, together totaling $17,000,000. Janel funded the acquisition with cash from operations, borrowings under its Senior Credit Facility, and issuance of the subordinated note.
In connection with the transaction, Janel and its lender group, led by Santander Bank, N.A. as administrative agent, entered into a Waiver, Consent, Joinder, and Second Amendment to Credit Agreement on October 16, 2026. The amendment increased acquisition facility commitments by $15,000,000, of which $11,000,000 was immediately funded by the lenders and used as cash consideration for the EnCor acquisition on October 20, 2026. The amendment also added an excess cash flow mandatory prepayment provision and included lender waivers and consent for provisions that would otherwise have restricted the acquisition.
EnCor was joined as a borrower under the Senior Credit Facility contemporaneously with the closing of the acquisition. Janel disclosed the transaction in a Form 8-K filed on October 22, 2026, with the underlying Purchase Agreement filed as an exhibit to that report.
The archive tags include a loan note. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- CompletedClosed
Janel Corporation completes acquisition of EnCor Biotechnology Inc.
Item 1.01 Entry into a Material Definitive Agreement Purchase Agreement On October 20, 2026, Janel Corporation, a Nevada corporation (the “Company”), through its wholly owned subsidiary Antibodies Incorporated, a California corporation (“Antibodies Inc.”), entered into a Purchase Agreement (the “Purchase Agreement”) with EnCor Biotechnology Inc., a Florida Corporation (“EnCor”), whereby Antibodies
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
Janel Corporation
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive